Investigation of granulomatous prostatitis incidence following intravesical BCG therapy

Basit Öğe Kaydı
dc.contributor.authorBalasar, Mehmet
dc.contributor.authorDogan, Metin
dc.contributor.authorKandemir, Abdulkadir
dc.contributor.authorTaskapu, Hakan Hakki
dc.contributor.authorCicekci, Faruk
dc.contributor.authorToy, Hatice
dc.contributor.authorGurbuz, Recai
dc.date.accessioned2024-02-23T14:45:54Z
dc.date.available2024-02-23T14:45:54Z
dc.date.issued2014
dc.departmentNEÜen_US
dc.description.abstractIn the present manuscript, we studied the incidence of granulomatous prostatitis in the prostatectomy specimen of the patients who underwent transurethral resection of the prostate (TURP) after superficial bladder cancer treatment with intravesical Bacillus Calmette-Guerin (BCG) and were diagnosed with benign prostate hyperplasia (BPH). The clinical data and histopathological specimen records of 472 patients who underwent TUR-P due to BPH diagnosis, obtained over a period of 6 years in the urology department of Private Konya Hospital, Konya, Turkey, were studied retrospectively. The cases were divided into two groups as (Group I) who did not undergo any treatment and as (Group II) who underwent BCG treatment. The frequency and the clinical course of the cases with granulomatous prostatitis were studied histopathologically. There were in total 472 patients who underwent TUR-P. Out of the 459 patients who did not undergo BCG treatment (Group I), the histopathological specimen records of 262 (57%) was BPH, of 197 (43%) BPH + chronic prostatitis. Of the second group, 13 cases underwent intravesical BCG treatment before surgical intervention due to superficial bladder CA diagnosis. In this group 4 of the cases were diagnosed as (30%) BPH, 9 as (70%) chronic prostatitis + BPH. 6 out of the 9 chronic prostatitis cases were chronic prostatitis, 2 caseous granulomatous prostatitis, 1 non-caseous granulomatous prostatitis. Granulomatous prostatitis cases should require no specific therapy. Conclusion: In patients with obstruction complaints following intravesical BCG treatment, granulomatous prostatitis should also be considered and treatment plans should be made accordingly.en_US
dc.identifier.endpage1557en_US
dc.identifier.issn1940-5901
dc.identifier.issue6en_US
dc.identifier.pmid25035779en_US
dc.identifier.scopus2-s2.0-84904035071en_US
dc.identifier.startpage1554en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12452/17675
dc.identifier.volume7en_US
dc.identifier.wosWOS:000341255900009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherE-Century Publishing Corpen_US
dc.relation.ispartofInternational Journal Of Clinical And Experimental Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGranulomatous Prostatitisen_US
dc.subjectIntravesical Bcg Immunotherapyen_US
dc.subjectTur-Pen_US
dc.titleInvestigation of granulomatous prostatitis incidence following intravesical BCG therapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu